A potential coronavirus treatment has failed in a randomized clinical trial in China. A group of Chinese researchers tested the HIV drug Kaletra in a group of patients with severe cases of COVID-19, the disease caused by the novel coronavirus, according to a report in Business Insider. Study results were published Wednesday in The New England Journal of Medicine.
The study enrolled 199 patients, with 99 receiving Kaletra in addition to standard of care and 100 receiving just standard of care. Patients receiving the HIV drug, which is made by AbbVie, got two doses per day for two weeks. The study was conducted at Jin Yin-Tan Hospital in Wuhan, China. Because of the emergency nature of the outbreak, the researchers wrote they did not have time to prepare a placebo for Kaletra, so doctors and patients knew which treatment they received.